DIPSS Plus Score for Prognosis in Myelofibrosis

The DIPSS was proposed and validated by Passamonti et al to estimate prognosis in myelofibrosis.

The DIPSS plus score further refines the prior prognostic scoring system with the addition of DIPSS-independent risk factors, including karyotype, transfusion dependency and platelet count. The score was developed and validated by Gangat et al.

Prognosis based on 6 point scoring system:

• If score is 0: Patient is considered "low risk" according to the DIPSS plus system. Median survival is estimated to be 180 months
• If score is 1: Patient is considered "intermediate-1 risk" according to the DIPSS plus system. Median survival is estimated to be 80 months
• If score is 2-3: Patient is considered "intermediate-2 risk" according to the DIPSS plus system. Median survival is estimated to be 35 months
• If score is 4 or more: Patient is considered "high risk" according to the DIPSS plus system. Median survival is estimated to be 16 months